NCT00748709 - Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2008

Primary Completion Date

November 1, 2010

Conditions

Neoplasms

Interventions

DRUG

BIBW 2992 (Afatinib)

BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation

Trial Locations (15)

1200.26.3 Boehringer Ingelheim Investigational Site, Los Angeles

1200.26.11 Boehringer Ingelheim Investigational Site, Denver

1200.26.9 Boehringer Ingelheim Investigational Site, Indianapolis

1200.26.1 Boehringer Ingelheim Investigational Site, Boston

1200.26.13 Boehringer Ingelheim Investigational Site, Las Vegas

1200.26.4 Boehringer Ingelheim Investigational Site, Albany

1200.26.2 Boehringer Ingelheim Investigational Site, New York

1200.26.7 Boehringer Ingelheim Investigational Site, Kettering

1200.26.12 Boehringer Ingelheim Investigational Site, Dallas

1200.26.8 Boehringer Ingelheim Investigational Site, Tyler

1200.26.6 Boehringer Ingelheim Investigational Site, Norfolk

1200.26.10 Boehringer Ingelheim Investigational Site, Vancouver

1200.26.88603 Boehringer Ingelheim Investigational Site, Tainan City

1200.26.88601 Boehringer Ingelheim Investigational Site, Taipei

1200.26.88602 Boehringer Ingelheim Investigational Site, Taoyuan District